Japan’s Shionogi, AstraZeneca Sue Seven Generics For Violating Crestor Patent (Japan)
This article was originally published in PharmAsia News
Executive SummaryJapan's Shionogi joined with AstraZeneca in suing seven makers of generic drugs for applying in the United States for a version of Crestor (rosuvastatin calcium) for lowering cholesterol. Shionogi, the developer, said its U.S. patent for the drug is still in effect and the application violates it. AstraZeneca markets the drug. Defendants in the suit are Apotex, Aurobindo Pharma, Cobalt Pharmaceuticals, Mylan Pharmaceuticals, Pan Pharmaceuticals, Sandoz and Sun Pharmaceuticals. (Click here for more - may require a subscription
You may also be interested in...
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker.
US FDA’s latest effort to provide guidance for consumers on pharmacogenomics tests underscores the challenges the agency faces in the absence of a clear regulatory framework for lab-developed tests – and with no easy mechanism to update labels for off-patent drugs.